3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
50
Stomach Neoplasms
7
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
HER2-positive Breast Cancer
3
Esophageal Neoplasms
3
Uterine Neoplasms
2
Solid Tumors
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Compliance
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Interventions
fludarabine phosphate
4
Cyclophosphamide
4
blinatumomab
3
Rituximab
3
Lenalidomide
2
Immunotherapy, Adoptive
2
venetoclax
1
trastuzumab deruxtecan
1
tisagenlecleucel
1
pembrolizumab
1
obinutuzumab
1
niraparib
1
nilotinib
1
isatuximab
1
acalabrutinib
1
Zymosan
1
Whole-Body Irradiation
1
Trastuzumab
1
Sodium Chloride
1
Sirolimus
1
Radiotherapy
1
Pentostatin
1
NKTR-255
1
Mycophenolic Acid
1
Melphalan
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Imatinib Mesylate
1
Histamine Antagonists
1
Exercise Test
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm, Residual
×
Trastuzumab
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled